OncLive® provides updates on the treatment of patients with diffuse large B-cell lymphoma through a Scientific Exchange Workshop.
Expert Perspectives in the Evolving Treatment Landscape of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Faculty debate the definitions of chemotherapy resistance, sensitivity, and refractoriness and discussed appropriate management strategies based on how patients would be classified in DLBCL.
Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Recent trials of novel therapies and therapeutic combinations have introduced promising options for the management of patients with relapsed or refractory diffuse large B-cell lymphoma.
Dr. Kahl on the Utility of Tafasitamab/Lenalidomide in DLBCL
Brad S. Kahl, MD, discusses the utility of tafasitamab combined with lenalidomide in patients with diffuse large B-cell lymphoma who are ineligible for CAR T-cell therapy.
Dr. Abdulhaq on the Benefits of Chemotherapy-Free Options in DLBCL
Haifaa Abdulhaq, MD, discusses the benefits of chemotherapy-free options in diffuse large B-cell lymphoma.
Dr. Flinn on Opportunities for Second-Line Tafasitamab in DLBCL
Ian W. Flinn, MD, PhD, discusses the opportunity for second-line tafasitamab (MOR208, formerly Xmab®5574) as a palliative treatment of patients with diffuse large B-cell lymphoma.
Dr. Abdulhaq on the Safety Profile of Tafasitamab in DLBCL
Haifaa Abdulhaq, MD, discusses the safety profile of tafasitamab (MOR208) in diffuse large B-cell lymphoma.
Dr. Kahl on Findings From the L-MIND Study With Tafasitamab in DLBCL
Brad S. Kahl, MD, discusses findings from the phase 2 L-MIND study in diffuse large B-cell lymphoma.
Dr. Flinn on the Utility of Tafasitamab in Relapsed/Refractory DLBCL
Ian W. Flinn, MD, PhD, discusses the utility of tafasitamab (MOR208) in patients with relapsed diffuse large B-cell lymphoma (DLBCL).
Dr Patel on the Potential for Adjuvant Immunotherapy in CSCC
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
Radioligand Therapies and Emerging Targets Drive Innovation in Prostate Cancer Management
Time-Limited Zanubrutinib/Rituximab Yields Durable Remissions in Treatment-Naive CLL
TAR-200 Is Poised to Become a Targeted, Tolerable Addition to BCG-Unresponsive NMIBC Treatment Arsenal
Efineptakin Alfa Represents Potentially Effective Option in Kaposi Sarcoma